Promising results were obtained in a recent phase III MARIPOSA-2 trial that evaluated the efficacy of amivantamab combined with chemotherapy, with or without lazertinib, versus chemotherapy alone in patients with advanced EGFR-mutant NSCLC who experienced disease progression after osimertinib treatment [243]. Here, EGFR is linked to non-small cell lung carcinoma.